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Abstract
Objectives: The objective was to assess the prognostic value of hypertension de-
tected in the emergency department (ED).
Methods: The ED presents a unique opportunity to predict long- term cardiovascular 
disease (CVD) outcomes with its potential for high- footfall, and large- scale routine 
data collection applied to underserved patient populations. A systematic review and 
meta- analyses were conducted to assess the prognostic performance and feasibility of 
ED- measured hypertension as a risk factor for long- term CVD outcomes. We searched 
MEDLINE and Embase databases and gray literature sources. The target populations 
were undifferentiated ED patients. The prognostic factor of interest was hypertension. 
Feasibility outcomes included prevalence, reliability, and follow- up attendance. Meta- 
analyses were performed for feasibility using a random effect and exact likelihood.
Results: The searches identified 1072 studies after title and abstract review, 53 studies 
had their full text assessed for eligibility, and 26 studies were included. Significant het-
erogeneity was identified, likely due to the international populations and differing study 
design. The meta- analyses estimate of prevalence for ED- measured hypertension was 
0.31 (95% confidence interval  0.25– 0.37). ED hypertension was persistent outside the 
ED (FE estimate of 0.50). The proportion of patients attending follow- up was low with an 
exact likelihood estimate of 0.41. Three studies examined the prognostic performance of 
hypertension and demonstrated an increased risk of long- term CVD outcomes.
Conclusion: Hypertension can be measured feasibly in the ED and consequently used 
in a long- term cardiovascular risk prediction model. There is an opportunity to inter-
vene in targeted individuals, using routinely collected data.
K E Y W O R D S
cardiovascular disease, emergency medicine, preventative medicine
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BACKGROUND
Cardiovascular disease (CVD) remains the leading cause of prema-
ture death in the western world.1 It is estimated that population- 
based primary prevention to reduce mean blood pressure and 
cholesterol by 10% would reduce the incidence of major CVD by 
45%.2 However, because important risk factors for CVD such as hy-
pertension and dyslipidemia are usually asymptomatic, identification 
of at- risk individuals can be challenging unless they regularly attend 
primary care appointments.
While there has been a tremendous technological advance that 
can allow the rapid diagnosis of acute coronary syndrome (ACS) in 
the emergency department (ED), few examine long- term CVD. In a 
feasibility study evaluating use of the Manchester Acute Coronary 
Syndromes (MACS) decision aid in practice,3 patients were dissatis-
fied with an approach that simply informed them that they “do not 
have ACS” and did not address future cardiovascular risk.
There were 23.4 million patient presentations to the United 
Kingdom's EDs in 2016, and this has been increasing by 10% each 
year, which is mirrored in the United States.4,5 The increase in ED 
attendance represents a paradigm shift in the way patients access 
health care, and although this has caused many previously noted 
problems, it also presents opportunity. Patients who do not see their 
primary care practitioner frequently are more likely to attend the ED. 
Therefore, the ED interaction is with a portion of society underserved 
by primary care.6 Preventative medicine is not a new concept to 
emergency medicine, and it has been previously researched and suc-
cessfully implemented.7 Patients demand and expect clinical staff in 
the acute care setting to have tools to inform them of their long- term 
cardiovascular risk.3 This presents an excellent opportunity for emer-
gency physicians to identify a large population of patients at high risk 
of future CVD, at a time when they are likely to be particularly recep-
tive. This systematic review sought to establish the evidence base for 
the predictor hypertension when measured in the acute care setting, 
which is commonly used in long- term cardiovascular risk prediction. 
The objective was to determine whether hypertension detected in 
the ED can be used to predict long- term CVD outcomes.
METHODS
We conducted a systematic review and meta- analysis in accordance 
with Preferred Reporting Items for Systematic Reviews (PRISMA) 
and meta- analysis guidelines and have registered on PROSPERO 
(CRD42018110517).8,9
Search question
The question structure of population, prognostic factor, and out-
come was used (PFO).10 The target population was ED patients and 
the outcome was long- term CVD outcomes (>12 months). The prog-
nostic factor of interest was hypertension.
Studies to be included were those that matched the PFO ques-
tion, conducted in the past 20 years, were randomized controlled 
trials or observational studies, and were conference abstracts or 
published/in press studies, in English language.
The prognostic factor of interest was hypertension measured 
in the ED, it was envisaged that the most widely available variable 
would be dichotomous around the common clinically significant 
threshold of 140/90 mmHg. The U.K. guidelines state that to diag-
nose hypertension serial readings should be used alongside ambula-
tory measurements or home blood pressure monitoring.11 It was not 
envisaged that this would be universal in the EDs but we planned 
to attempt sensitivity analysis of the different measurement tech-
niques if possible, to attempt to detect any effect it may have had on 
measurement.12
Outcome measurement
We examined the feasibility of the measurement of hypertension 
and its prognostic characteristics for cardiovascular outcomes. 
Feasibility measures included study prevalence, persistence of ab-
normal readings, and proportion of patient attendance for follow- up. 
The cardiovascular outcomes included acute myocardial infarction, 
coronary revascularisation, coronary heart disease, angina, stroke, 
transient ischemic attack, cerebrovascular event, and death (all 
cause and CVD).
Search methods for identification of studies
Information sources
The following traditional and gray information sources were 
searched independently by two researchers: the electronic da-
tabases MEDLINE and Embase (see Data Supplement S1 [avail-
able as supporting information in the online version of this paper, 
which is available at http://onlin elibr ary.wiley.com/doi/10.1111/
acem.14324/ full] for search terms), International Committee of 
Medical Journal Editors, World Health Organization– International 
Clinical Trials Registry Platform, World Medical Association, British 
Library Thesis, secondary reference checking, guideline clearing 
house (https//www.guide lines.com), and University of Manchester 
library search; and the opinion of experts in the field, Professor 
Richard Body and Professor Tony Heagerty.
Data collection
The studies returned from the initial searches had their title and 
abstract screened by two independent clinical– academic review-
ers. Selected papers then underwent full- text review by the same 
researchers; when disagreement occurred a third independent re-
searcher reviewed the paper and agreement was met by consensus. 
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Bespoke electronic study and data collection forms were created 
for the purpose of the systematic review. We used the Quality In 
Prognosis Studies (QUIPS) tool to analyze the risk of bias in each 
prognostic factor study.13
To measure the value of the prognostic factor, we extracted data 
with a preference toward hazard ratio and adjusted measures. To 
assess heterogeneity we calculated I2 and when a large outlier was 
identified examined the effect of removal.
Data synthesis
If fewer than three studies reported the estimate of interest, a nar-
rative review is given. Otherwise, a meta- analysis is performed, 
using a random effect and exact likelihood for binomial distribution 
described by Hamza et al.14 to accommodate the heterogeneity be-
tween studies. We used the statistical software R, including pack-
ages metaphor and ggplot2.15– 17
RESULTS
Search result s
All searches were conducted on the October 27, 2020. We identified 
1,072 studies, of which 725 were unique. After title and abstract 
review, 53 studies had their full text assessed for eligibility, and 26 
studies were included (Figure 1): 17 were from the United States; 
F I G U R E  1  Flowchart of blood pressure study selection process
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two from the United Kingdom; and one each from Australia, Canada, 
South Korea, Israel, Iran, Sweden, and Hong Kong (Table 1). There 
were 11 prospective studies with the majority being retrospective. 
There was a large range in population size; McNaughton et al.18 
had by far the most participants at nearly 702 million, the implica-
tions of which are discussed later. Fifteen of the studies reported 
an estimate of prevalence18– 32 and the persistence of hyperten-
sion in eight studies within the ED20,23,26,31,33– 36 and 12 outside of 
ED.19,20,22,28,30,31,36– 41 Follow- up attendance was reported in eight 
studies20,22,29,30,33,36,39,40 and three reported the prognostic perfor-
mance of hypertension for CVD.32,42,43
Risk of  b ias within studies
The QUIPS tool was used to analyze the risk of bias; none were found 
to have a high risk of bias. Only two studies, Tanabe et al.37 and Shiber- 
Ofer et al.,38 were found to have a low risk of bias with the remainder 
being rated moderate. Most demonstrated a moderate risk in the study 
participation domain for inclusion criteria. Some studies accounted for 
the potential confounders of fear and anxiety.19,35– 37 They all demon-
strated a persistence of hypertensive readings despite the presence of 
these factors. The failure to account for these potential confounders 
was deemed to be a moderate risk of bias for this domain.
Prevalence of  hyper tensive readings
The prevalence of a single hypertensive reading (≥140/90 mmHg) 
ranged from 0.16 to 0.6221,31 and there was significant heterogeneity 
with the percentage of variation across studies estimated at 99.7% (I2). 
This is possibly due to the variety of populations included and different 
trial designs. Meta- analysis resulted in an estimated pooled study prev-
alence of 0.31 (95% confidence interval [CI] = 0.25 to 0.37). The largest 
study, McNaughton et al.,18 was removed in a sensitivity analysis and 
the resulting estimate was 0.31 (95% CI = 0.25 to 0.39; Figure 2).







period Follow- up Outcome measure
Risk of 
bias
Adhikari, United States, 201635 R 179 ED 2011 N/A BP advice M
Backer, United States, 200336 P 407 3 × ED 2000 6 months F/U BP M
Baumann, United States, 200723 P 991 3 × Researcher 2004 N/A Descriptive M
Baumann, United States, 200926 R 4,245 ED 2005– 2006 N/A Repeat ED BP M
Cienki, United States, 201334 R 1,000 ED 2005– 2010 N/A BP advice M
Cline, United States, 200639 R 1,391 EPR 2003– 2004 3 months Secondary care F/U M
Collins, UK, 200822 P 765 2 x Researcher 2005– 2006 6 months Primary care F/U M
Dolatabadi, Iran, 201428 P 346 2 x ED 2009 – 2010 30 day Prevalence M
Fleming, UK, 200519 P 991 2 x Researcher 2004 30 days Sustained HTN M
Goldberg, United States, 201731 P 151 3 x Researcher 2014– 2017 2 weeks Sustained HTN M
Julliard, United States, 201230 R 662 EPR 2009 3 months Primary care F/U M
Karras, United States, 200520 P 7,238 1 X ED 2002 30 day Primary care F/U M
Lee, South Korea, 2018 42 R 262.927 EPR 2002– 2013 10 years MACE M
Masood, Canada, 201643 R 206,147 EPR 2002– 2012 2 years All- cause mortality M
McNaughton, United States, 201518 R 701,952,422 EPR 2006– 2012 N/A Descriptive M
Meurer, United States, 201941 P 201 1 x ED 1 x self 
reported
2014– 2015 3 months Sustained HTN M
Oras, Sweden, 202032 R 300,193 EPR 2010– 2016 6 years MACE M
Shah, United States, 201127 R 601 EPR 2009– 2010 N/A F/U M
Shiber- Ofer, Israel, 201538 P 195 ED 2009– 2010 5 years F/U BP L
Souffront, United States, 201633 R 2,367 EPR 2014– 2015 N/A N/A M
Svenson, United States, 200824 R 2,821 EPR 2006 1 year Descriptive M
Tan, Australia, 201329 P 534 1 x Researcher 2010– 2011 5 weeks Descriptive M
Tanabe, United States, 200837 P 175 2 x ED 2005– 2006 1 week Sustained HTN L
Tilman, United States, 200721 R 1,574 EPR 2004 N/A BP advice M
Tsoi, Hong Kong, 201240 P 245 2 x ED 2010 2 weeks Primary care F/U M
Umscheid, United States, 200825 R 2,061 EPR 2005 N/A Descriptive M
Abbreviations: R = retrospective; P = prospective; EPR = electronic patient record; N/A = not applicable; F/U = follow- up; HTN = hypertension; 
BP = blood pressure; MACE = major adverse cardiac events; H = high risk of bias; M = moderate risk of bias; L = low risk of bias.
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Persistence of  hyper tensive readings
The persistence of hypertensive readings within the ED ranged from 
0.44 to 0.71,31,35 an I2 of 0.84 demonstrating moderate heterogene-
ity. The pooled estimate of ED persistence was 0.62 (95% CI = 0.56 
to 0.68; see Figure 3).
The persistence of hypertensive readings in the outpatient set-
ting ranged from 0.26 to 0.88;20,30 however, significant heteroge-
neity was detected with an I2 of 90.2%. The pooled estimate for 
persistence of hypertensive reading in the outpatient setting was 
found to be 0.50 (95% CI = 0.38 to 0.61; see Figure 4).
Propor t ion of  at tendance at  fo l low- up
The proportion of attendance at follow- up ranged from 0.02 to 
0.6533,36 and demonstrated significant heterogeneity with an of I2 
97.3%. The estimated pooled proportion was 0.41 (95% CI = 0.23 to 
0.62; see Figure 5).
Prognost ic  va lue
Masood et al.,32 Lee et al.,42 and Oras et al.43 were the only stud-
ies that reported on the prognostic value of hypertensive readings 
for long- term cardiovascular outcomes. All were large retrospective 
population registry studies from Canada, South Korea, and Sweden, 
respectively. Among 206,147 Canadian ED patients with a coded di-
agnosis of hypertension, mortality at 2 years for discharged patients 
was 3.59% (95% CI = 3.51 to 3.68), and complications of hypertension 
were 9.3%.43 The South Korean database contained 262,927 noncriti-
cal first ED attendances42 from which Lee et al.42 explored the as-
sociation between ED- coded hypertension and major adverse cardiac 
events (MACE). The outcome of MACE at 0 to 3 years resulted in an 
estimated hazard ratio of 4.25 (95% CI = 3.83 to 4.71), for MACE at 4 
to 6 years the estimated hazard ratio was 3.65 (95% CI = 3.14 to 4.24), 
and at 7 to 10 years 3.20 (95% CI = 2.50 to 4.11) for an ED- coded 
hypertension. The Swedish retrospective study included 300,193 
patients and examined hazard ratios for the outcome incident ath-
erosclerotic CVD, which was very similar to Lee et al.'s definition of 
TA B L E  2  Risk of bias in studies examining hypertension
Author, Year Domain 1 Domain 2 Domain 3 Domain 4 Domain 5 Domain 6 Overall
Adhikari, 2016 35 Moderate Low Moderate N/A Moderate Low Moderate
Backer, 200336 Moderate Low Low Low Moderate Low Moderate
Baumann, 200723 Low Low Low Low Low Moderate Moderate
Baumann, 200926 Moderate Low Moderate N/A Moderate Moderate Moderate
Cienki, 201334 Low Low Moderate Moderate Moderate Moderate Moderate
Cline, 200639 Moderate Moderate Moderate Moderate Moderate Moderate Moderate
Collins, 200822 Moderate Low Low Low Low Moderate Moderate
Dolatabadi, 201428 Low Moderate Low Low Low Moderate Moderate
Fleming, 200519 Low Moderate Low Low Low Low Moderate
Goldberg, 201731 Low Low Low Low Moderate Low Moderate
Julliard, 201230 Moderate Moderate Low Moderate Moderate Low Moderate
Karras, 200520 Low Low Moderate Moderate Moderate Moderate Moderate
Lee, 201842 Moderate Moderate Moderate Low Moderate Low Moderate
Masood, 201643 Moderate Moderate Moderate Moderate Moderate Low Moderate
McNaughton, 201518 Moderate Moderate Moderate N/A Moderate Moderate Moderate
Meurer, 201941 Low Moderate Moderate Low Low Low Moderate
Oras, 202032 Low Low Moderate Moderate Moderate Low Moderate
Shah, 201127 Moderate Low Moderate Moderate Moderate Moderate Moderate
Shiber- Ofer, 201538 Low Low Low Low Low Low Low
Souffront, 201633 Moderate Low Low Moderate Low Moderate Moderate
Svenson, 200724 Moderate Moderate Low Low Moderate Low Moderate
Tan, 201329 Low Low Low Low Low Moderate Moderate
Tanabe, 200837 Low Low Low Low Low Low Low
Tilman, 200621 Low Low Low Low Moderate Low Moderate
Tsoi, 201240 Low Low Low Low Low Moderate Moderate
Umscheid, 200825 Moderate Low Low Moderate Low Low Moderate
Note: This was conducted using the QUIPs tool.20 Domain 1 = study participation; domain 2 = study attrition; domain 3 = prognostic factor 
measurement; domain 4 = outcome measurement; domain 5 = study confounding; domain 6 = statistical analysis and reporting.
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MACE.32 This study reported adjusted hazard ratios stratified by 
grade of hypertension and it demonstrated a exposure– response re-
lationship. A systolic blood pressure (SBP) of 140 to 159 mm Hg had 
a hazard ratio of 1.24 (95% CI = 1.09 to 1.41), sBP 160 to 179 mm Hg 
had a HR of 1.62 (95% CI = 1.42 to 1.85), and an SBP greater than 
180 mm Hg demonstrated a HR of 2.02 (95% CI = 1.75 to 2.33).
DISCUSSION
Among the 26 included studies, study prevalence of hypertensive 
readings was the most reported and consisted of mainly moderately 
biased studies (Table 2). The prevalence of ED hypertension was fre-
quently adjusted for pain and we estimated the pooled prevalence of 
F I G U R E  2  Meta- analysis forest plot of the prevalence of hypertensive readings in the ED without McNaughton et al. Exact likelihood 
estimation19– 32
F I G U R E  3  Meta- analysis forest plot of the persistence of hypertensive readings the ED. Exact likelihood estimation20,23,26,31,33– 36
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ED hypertension as 0.31 (95% CI = 0.25 to 0.37). Hypertension was 
found to be persistent within ED multiple readings (62% remained 
hypertensive) and at follow- up (50%). This suggests that observing 
hypertension within the ED can not only be indicative of persistent 
hypertension but there was evidence that hypertensive ED read-
ings were associated with an increased risk of long- term CVD out-
comes.42,43 Inviting the patient back to an outpatient clinic for 
confirmatory testing could be the obvious and classical approach. 
F I G U R E  4  Meta- analysis forest plot of the persistence of hypertensive readings at follow- up. Exact likelihood 
estimation19,20,22,28,30,31,36– 41
F I G U R E  5  Meta- analysis forest plot of the proportion of attendance at follow- up for hypertension. Exact likelihood 
estimation20,22,29,30,33,36,39,40
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However, given our pooled estimates of 41% attendance at follow-
 up this might fail to capture a significant proportion of patients and 
indicate that a different model is needed. Consequently, acting 
within the ED visit could be beneficial, avoiding this loss to follow-
 up. Bowen et al.44 described outcomes of interest for feasibility; in 
keeping with this review, we have shown the likely demand for such 
a service in the prevalence and persistence estimates, and the suc-
cess or failure of execution via the rate of attendance at follow- up. 
This supports the hypothesis that ED hypertension could be feasibly 
acted upon and utilized for long- term CVD prediction tools within 
the ED setting.
There are recent studies demonstrating no benefit when treat-
ing hypertension identified in admitted patients; however, these 
focus on relatively short- term CVD outcomes (<3 years).45 CVD is 
a disease with outcome time scales classically over decades; there-
fore, this short- term reassurance appears to be masking a long- term 
problem. As the ED can feasibly detect hypertension and it has been 
shown to be predictive of long- term outcomes, we may have a duty 
to intervene in some capacity.
LIMITATIONS
Significant heterogeneity was identified; it appeared to be primar-
ily due to differing practices in prognostic factor measurement, 
difference in acuity, country, and type of study. Furthermore, we 
included a variety of study types and, therefore, the estimates of 
prevalence should be generalized with caution. The prevalence and 
persistence are still substantial even when the lower bounds of the 
CIs are assumed to be correct. This would indicate that despite the 
significant heterogeneity, ED hypertensive readings are still, likely, 
of prognostic value. This systematic review included international 
studies. While this added new studies and evidence it also limits the 
precision of the estimations when generalized to a specific popula-
tion and system.
CONCLUSIONS
We have found that ED hypertension was prevalent, persistent, and 
predictive of long- term cardiovascular outcomes. These findings 
must be interpreted in the context of the large heterogeneity en-
countered in our review, which was likely due to the diverse popula-
tions included.
The American College of Emergency Physicians already recom-
mends that hypertensive readings are acted upon either by out-
patient follow- up or immediate therapy.46 In the context of this 
review this advice appears sensible and should be heeded interna-
tionally. This could be through a targeted intervention with a clin-
ical prediction model. However, careful thought is required prior 
to any service implementation as follow- up attendance was low. 
Even with this potential shortcoming, this represents an enormous 
opportunity for well- designed screening and intervention care 
pathways in a high- risk population. Current research is ongoing 
examining the long- term prognostic ability of routinely collected 
data and the practicalities of implementation of a care pathway 
through qualitative studies.47
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